| Literature DB >> 27252918 |
Masoud Yousefi1, Mohammad Reza Pourmand2, Fatemeh Fallah1, Ali Hashemi1, Rahil Mashhadi3, Ali Nazari-Alam1.
Abstract
BACKGROUND: The aim of this study was to investigate the antibiotic susceptibility pattern as well as the phenotypic and genotypic biofilm formation ability of Staphylococcus aureus isolates from patients with urinary tract infection (UTI).Entities:
Keywords: Antibiotic resistance; Biofilm formation; Staphylococcus aureus; Urinary tract infection
Year: 2016 PMID: 27252918 PMCID: PMC4888176
Source DB: PubMed Journal: Iran J Public Health ISSN: 2251-6085 Impact factor: 1.429
Classification of biofilm formation abilities by microtiter plate method
| OD > 4×ODc | OD > 0.236 | Strong |
| 2×ODc < OD ≤4×ODc | 0.118< OD ≤ 0.236 | Moderate |
| ODc< OD ≤ 2×ODc | 0.059< OD ≤ 0.118 | Weak |
| OD ≤ 0.059 | OD ≤ 0.059 | None |
Target genes and their primers used in this study
| Fw- CAATCAAGGCATTAAACAGGCTTC | 509 | 62 | This study | |
| Fw- GATACAAACCCAGGTGGTGG | 191 | 55 | (
| |
| Fw- ATTCTGCTGTTAAAGGTGACACAT | 657 | 62 | This study | |
| Fw- CCCTATATCGAAGGTGTAGAATTG | 971 | 62 | ( |
Fig. 1:Antimicrobial resistance pattern of S. aureus isolates (MRSA and MSSA).
Fig. 2:Colony morphologies of S. aureus isolates on the modified Congo red agar medium
Biofilm production S. aureus isolates in microtiter plate and Congo red agar method
| Modified Congo red agar | Very black | 3 | 33.3 | 1 | 3.3 | 4 | 10.2 |
| Black | 4 | 44.5 | 11 | 36.7 | 15 | 38.5 | |
| Almost black | 1 | 11.1 | 7 | 23.3 | 8 | 20.5 | |
| Red | 1 | 11.1 | 11 | 36.7 | 12 | 30.8 | |
| Microtiter plate assay | Strong | 3 | 33.3 | 5 | 16.6 | 8 | 20.5 |
| Moderate | 3 | 33.3 | 8 | 26.7 | 11 | 28.2 | |
| Weak | 2 | 22.2 | 6 | 20 | 8 | 20.5 | |
| None | 1 | 11.1 | 11 | 36.7 | 12 | 30.8 |
Antimicrobial resistance pattern and phenotypic biofilm formation in S. aureus isolates
| Erythromycin | 14 (56) | 11 (44) | 0 (0) | 0 (0) | 13 (92.9) | 1 (7.1) |
| Ciprofloxacin | 14 (56) | 11 (44) | 0 (0) | 0 (0) | 13 (92.9) | 1 (7.1) |
| Tetracycline | 15 (57.7) | 11 (42.3) | 0 (0) | 0 (0) | 12 (92.3) | 1 (7.7) |
| Chloramphenicol | 0 (0) | 1 (100) | 0 (0) | 0 (0) | 27 (71.1) | 11 (28.9) |
| Rifampin | 8 (57.1) | 6 (42.9) | 0 (0) | 0 (0) | 19 (76) | 6 (24) |
| Nitrofurantoin | 5 (71.4) | 2 (28.6) | 10 (62.5) | 6 (37.5) | 12 (75) | 4 (25) |
| Linezolid | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 27 (69.2) | 12 (30.8) |
| Quinupristin/Dalfopristin | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 27 (69.2) | 12 (30.8) |
| Clindamycin | 12 (54.5) | 10 (45.5) | 0 (0) | 0 (0) | 15 (88.2) | 2 (11.8) |
| Doxycycline | 5 (45.5) | 6 (54.5) | 7 (58.3) | 5 (41.7) | 15 (93.8) | 1 (6.3) |
| Trimethoprim-Sulfamethoxazole | 4 (44.4) | 5 (55.6) | 0 (0) | 0 (0) | 23 (76.7) | 7 (23.3) |
| Gentamicin | 12 (52.2) | 11 (47.8) | 0 (0) | 0 (0) | 15 (93.8) | 1 (6.3) |
Fig. 3:Amplification of icaA, fnbA, clfA genes from S. aureus isolates.
Lane M, DNA marker (100 bp); Lane1 and 2, clfA (657 bp); Lane 4 and 5, fnbA (191 bp);
Lane 7 and 8, icaA (509 bp); Lane 3, 6 and 9, negative controls